Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

By: Investor's Business Daily

Nov 03 2024
0
0 Views

Madrigal stock catapulted higher again Friday after Novo Nordisk (NVO) published promising but not "game-changing" results for its weight-loss drug in patients with a liver disease. XNOW PLAYINGHow … [+3626 chars]

Amazon’s Big Spending Is Getting a Pass From Investors. Here’s Why. - Barron's

The Trump Betting Whale Speaks Out: ‘I Have Absolutely No Political Agenda’ - The Wall Street Journal

Trump loses $2.4 billion in net worth after his social media stock implodes right before the election - CNN

Oil prices settle up slightly on Iran worries, but prices down for week - Reuters

Apple Earnings Confirmed One Thing — Nobody Knows When a Major Upgrade Cycle Is Coming - Barron's

IRS increases 401(k), other retirement plan contribution limits for 2025 - Fox Business

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network